Forecast

The analysts' average price target is +33,49€ (−4,94%). The median is +33,49€ (−4,94%).

Buy	5
Hold	5
Sell	0

News Go to news feed

XOMA reports profitable year: license revenues up 68% and portfolio grows to over 120 assets

XOMA reports portfolio revenues of $50.5 million for 2025 and strong license revenue growth of 68% to $33.6 million. The company recorded GAAP net income of $31.7 million, expanded its portfolio through 11 transactions to more than 120 assets, and repurchased $16 million of shares. XOMA held $83 million in cash at year-end, sees several near-term drivers for 2026, but continues to face litigation and debt-related interest costs. » More on de.investing.com
XOMA Royalty completes acquisition of Generation Bio, GBIO to be delisted from Nasdaq

XOMA Royalty has completed the acquisition of Generation Bio and, through its subsidiary XRA 7 Corp., acquired all outstanding common shares at $4.2913 per share plus a non-tradable contingent value right (CVR). Around 70% of the shares were tendered; after closing Generation Bio is a wholly owned subsidiary of XOMA Royalty and the remaining shares were automatically converted at the same price. Nasdaq has suspended trading in the GBIO share and the company will be delisted, cease its SEC reporting obligations and have its registration cancelled. In connection with the merger the entire board of directors and management of Generation Bio resigned, operational leadership was assumed by Owen Hughes; the headquarters lease was terminated in exchange for a lump-sum payment of about $21.5 million. » More on de.investing.com
XOMA adjusts licensing agreement with Takeda: Takeda buys back majority of royalties for Mezagitamab

XOMA Royalty and Takeda renegotiated their licensing agreement: Takeda is buying back most of XOMA’s claims to royalties for Mezagitamab, while XOMA retains a royalty in the low single-digit percentage range and entitlement to reduced milestone payments of up to USD 13 million. In return, XOMA will receive royalties and milestone payments going forward for nine development candidates from Takeda’s portfolio that were licensed to third parties, including Osavampator, Volixibat, OHB-607 and REC-4881. The transaction is intended to diversify XOMA’s portfolio of royalties and milestones and represents a strategic realignment. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2022, XOMA has already paid 0,48€ in dividends. The last payout was in January 2022.

Financials

In the last quarter, XOMA had revenue of 10.64m€ and net profit of 3.86m€

(EUR)	Mar 2026	YoY
Revenue	+10.64m	27,65%
Gross profit	+9.87m	30,53%
Net profit	+3.86m	76,30%
EBITDA	+7.53m	27,72%

Fundamentals

Metric	Value
Market capitalization	+432.59m€
Number of shares	12.54m
52-week high/low	+38,83€ - +19,14€
Dividends	No
Beta	0,87
P/E ratio	+24,35
PEG ratio	−0,17
P/B ratio	+4,23
P/S ratio	+13,90

Company profile

Die XOMA Corporation ist in Europa, den Vereinigten Staaten und im asiatisch-pazifischen Raum als Aggregator für Biotechnologie-Lizenzgebühren tätig. Das Unternehmen unterstützt Biotech-Unternehmen bei der Verbesserung der menschlichen Gesundheit. Es erwirbt die potenzielle zukünftige Wirtschaftlichkeit, die mit vorkommerziellen therapeutischen Kandidaten verbunden ist, die an Pharma- oder Biotechnologieunternehmen lizenziert wurden. Das Unternehmen konzentriert sich auf frühe bis mittlere klinische Wirkstoffe, vor allem in Phase 1 und 2, mit kommerziellem Verkaufspotenzial, die an Partner lizenziert werden. Das Unternehmen verfügt über ein Portfolio mit etwa 70 Produkten. Die XOMA Corporation wurde 1981 gegründet und hat ihren Hauptsitz in Emeryville, Kalifornien.